U.S. panel rejects ovarian cancer screens for low-risk women

September 10, 2012 by Amanda Gardner, Healthday Reporter
U.S. panel rejects ovarian cancer screens for low-risk women
Renewing prior recommendations, experts say current tests not worth it for most.

(HealthDay)—A leading U.S. government panel has recommended against ovarian cancer screening for women who are not at high risk for the disease.

The blood test and transvaginal ultrasound that are currently used to spot may cause more harm than benefit for those patients, according to final guidelines issued Monday by the U.S. Preventive Services . who have the (BRCA1/) or family histories that raise their chances of developing ovarian cancer should be referred for genetic testing and counseling, the recommendations add.

These latest guidelines, which were also published Sept. 11 in the , mirror those set by the task force back in 2004.

"There is no existing method of screening for ovarian cancer that is effective in reducing deaths," Dr. Virginia Moyer, chair of the U.S. Task Force, said in a USPSTF statement issued Monday. "In fact, a high percentage of women who undergo screening experience false-positive test results and consequently may be subjected to unnecessary harms, such as major surgery," she said.

"In light of this, there is a critical need to develop better screening tests for ovarian cancer," Moyer added.

Experts agreed that effective tests to screen for ovarian cancer are desperately needed.

"It is very important that the population at large understands that screening with [ultrasound] and CA 125 is not beneficial at this time," said Dr. Diana Contreras, director of gynecologic oncology at Long Island Jewish Medical Center in New Hyde Park, N.Y. "It is clear new avenues need to be pursued, and women need to insist that more research is performed attempting to find an adequate screening mechanism so that ovarian cancer can be detected at a curable stage."

In addition, Dr. Elizabeth Poynor, a and pelvic surgeon at Lenox Hill Hospital in New York City, said: "The task force statement highlights the need for innovations and ongoing clinical investigation in ovarian cancer screening techniques. Women should review with their health care providers the early warning signs and symptoms of ovarian cancer, as well as their family and personal health histories in order to develop individualized strategies for risk reduction. Women should be offered participation in clinical trials in ovarian , when available and appropriate," she added.

Dr. David Grossman, a member of the task force and senior investigator with Group Health Research Institute in Seattle, said that "the tests that we have, unfortunately, just aren't very accurate and, with a lot of false positives, a lot of women get harmed with unnecessary biopsies and surgeries."

A large study published last year found no difference in mortality between women who were randomly assigned to receive a blood test plus the ultrasound compared to those who had "usual care."

What's more, some 10 percent of women who underwent screening received a false-positive result and one-third of these had an ovary removed unnecessarily.

Another study estimated that 33 surgeries were needed to diagnose one case of ovarian cancer using the blood test/ultrasound screening.

Preliminary data from yet another trial, ongoing in the United Kingdom, also turned up false-positive results in about 10 percent of women undergoing screening. Half of those women had surgery and about 4 percent of these experienced a major complication from the surgery.

Like many screening tests, the blood test plus ultrasound for ovarian cancer "doesn't work, is potentially dangerous and also costs a lot of money," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "You're giving people a false sense of security, and it creates a lot of false positives, which ultimately results in a lot of unnecessary surgeries."

The task force's recommendations are also in line with recommendations from the American Cancer Society and the American Congress of Obstetricians and Gynecologists (ACOG), Grossman said.

This leaves women with no good test to screen for ovarian cancer, considered a "silent killer" because symptoms are often noticed too late to be treatable.

And there are no other techniques on the horizon, Grossman added.

Explore further: U.S. panel rejects ovarian cancer screening

More information: The U.S. National Cancer Institute has more on ovarian cancer.


Related Stories

U.S. panel rejects ovarian cancer screening

April 10, 2012
(HealthDay) -- A leading U.S. government panel has renewed its 2004 recommendation that women at average risk for ovarian cancer not get screened for the disease.

Ovarian cancer screening does not appear to reduce risk of ovarian cancer death

June 5, 2011
In a clinical trial that included nearly 80,000 women, those who received ovarian cancer screening did not have a reduced risk of death from ovarian cancer compared to women who received usual care, but did have an increase ...

Depression affected preventive health screening among Latina breast cancer survivors

September 19, 2011
Depression, in addition to other barriers, may prevent Latina breast cancer survivors from undergoing preventive health screening for colorectal and ovarian cancer, according to data presented at the Fourth AACR Conference ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Scientists develop blood test that spots tumor-derived DNA in people with early-stage cancers

August 16, 2017
In a bid to detect cancers early and in a noninvasive way, scientists at the Johns Hopkins Kimmel Cancer Center report they have developed a test that spots tiny amounts of cancer-specific DNA in blood and have used it to ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.